Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis

PR Newswire
February 28, 2022 — 08:00 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: China chinese Economy Education Hangzhou healthcare medicine University

Related News:

Jean-Michel Jarre is world’s first passenger to take off in KleinVision’s flying AirCar

April 24, 2024 — 13:00

Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever

April 24, 2024 — 13:00

Zepp Health Corporation Files 2023 Annual Report on Form 20-F

April 23, 2024 — 20:20

TTC Announces Strategic Expansion into Western Australia with New Perth Office

April 23, 2024 — 04:00

Tantech Holdings Ltd Announces $2.1 Million Private Placement

April 23, 2024 — 03:58

Latham Adds Experienced M&A Partner in Tokyo

April 23, 2024 — 03:15

GT20029 China Phase II Trial For AGA Reached Primary Endpoint

April 22, 2024 — 09:53

Mayur achieves major milestone with US$155 million for Central Lime Project in Papua New Guinea

April 22, 2024 — 09:38

Four World Records Set Weichai Power Unveils World’s First Diesel Engine with 53.09% Thermal Efficiency

April 20, 2024 — 20:19